Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells

Table 4 Distribution of mutations across targets and samples

Sample	Diagnosis	Cohort	BRAF_15	EGFR_20	EGFR_21	ERBB2	PIK3CA_10	TP53_5	TP53_6	TP53_7	Total
946	CA	SMK	1	0	0	0	0	0	1	0	2
167	CA	SMK	0	3	0	1	0	1	3	3	11
947	CA	SMK	0	2	0	1	1	0	0	1	5
146	CA	SMK	1	3	1	1	0	1	0	0	7
887	CA	SMK	0	4	0	1	0	1	0	1	7
885	CA	SMK	0	3	0	0	0	4	2	1	10
940	CA	SMK	0	0	0	0	1	6	6	2	15
191	CA	SMK	0	3	0	2	1	2	5	1	14
147	CA	SMK	1	3	0	1	1	4	4	0	14
128	CA	SMK	0	3	0	1	0	0	1	0	5
923	CA	SMK	0	1	0	1	0	2	4	1	9
210	NC	SMK	0	3	0	1	0	0	0	0	4
886	NC	NON	0	2	0	1	0	0	0	0	3
952	NC	SMK	0	1	0	1	0	1	0	0	3
157	NC	SMK	0	2	0	1	0	0	0	1	4
943	NC	NON	0	3	0	1	0	0	1	0	5
956	NC	SMK	0	3	0	1	0	1	0	0	5
884	NC	SMK	0	1	0	1	0	0	0	0	2
883	NC	NON	0	3	0	1	0	0	0	0	4
Total			3	43	1	17	4	23	27	11	129

Inter-target and inter-sample distribution of mutations. Mutations were defined as those with VAF (variant allele reads/total allele reads) > 5 × 10⁻⁴ (0.05%) and significantly above IS background VAF based on contingency table analysis

ISSN: 1471-2407